Clinical Trial Update: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase III open-label study evaluating durvalumab with or without tremelimumab versus standard-of-care in first-line non-small cell lung cancer; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Carcinoma NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-11-29